STAUROSPORINE CAUSES A MUSCLE PHENOTYPE DEPENDENT ATROPHY IN SKELETAL MUSCLE OF MICE VIA CASPASE-9 GENE INDUCTION AND DOWNREGULATION OF SUR2A GENE
Camerino G., Mele A., Calzolaro S., Cannone M., Tricarico D. |
INVOLVEMENT OF THE L-CYSTEINE/HYDROGEN SULPHIDE PATHWAY IN HUMAN MELANOMA.
De Cicco P., Panza E., Bucci M., Cirino G., Ianaro A. |
ANTIPROLIFERATIVE ACTIVITY OF BERGAMOT JUICE EXTRACT IN HUMAN COLON CANCER CELLS
Cirmi S., Visalli G., Lombardo G., Ferlazzo N., Di Pietro A., Navarra M. |
GLYCOGEN SYNTHASE KINASE CONTROLS AUTOPHAGY DURING RENAL ISCHEMIA/REPERFUSION
Paterniti I., Ahmad A., Campolo M., Esposito E., Cuzzocrea S. |
ANTIPROLIFERATIVE EFFECTS OF NEW VANADYL COMPLEXES WITH ACETILACETONATE DERIVATIVES ON NON-TUMOR AND TUMOR CELL LINES
Boscaro V., Sgarbossa S., Diana E., Marabello D., Deagostino A., Cadamuro S., Barge A., Laurenti E., Ghibaudi E., Gallicchio M. |
IN VIVO EVALUATION OF NEW THERAPEUTIC APPROACHES FOR THE TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
Ruocco M., Angelucci S., D'Amico M., Hrelia P., Tonelli R., Montemurro L., Pession A. |
EFFECT OF CITRUS BERGAMIA JUICE IN A XENOGRAFT MODEL OF NEUROBLASTOMA METASTASIS FORMATION
Navarra M., Ursino M., Cirmi S., Lombardo G., Ferlazzo N., Schumacher U., Valentiner U. |
EFFECT OF MCP-1 INHIBITORS ON PROSTATE TUMOR GROWTH
di Matteo A., Castaldi W., De Santi S., Amato A., Coletta I., Garrone B., Durando L. |
ANTICANCER ACTIVITY OF ANANDAMIDE IN HUMAN CUTANEOUS MELANOMA CELLS
Adinolfi B., Romanini A., Vanni A., Martinotti E., Chicca A., Fogli S., Nieri P. |
INTRACELLULAR PATHWAYS INVOLVED IN CANNABIDIOL ANTI-PROLIFERATIVE EFFECT IN U87-MG AND T98G GLIOMA CELL LINES
Cinquina V., Solinas M., Parolaro D. |
EXPRESSION OF A SPECIFIC THYMIDYLATE SYNTHASE POLIMORFIC ALLELE IN METASTATIC COLORECTAL PATIENTS IS REGULATED BY MYELOID ZINC FINGER 1.
Calascibetta A., Martorana A., Labbozzetta M., Sanguedolce R. |
TRANSCRIPTION FACTOR REST DOES NOT AFFECT ACETYLATION OF H3 HISTONE INDUCED BY VALPROIC ACID IN HELA CELLS
Khodeneva N., Baiula M., Spampinato S. |
ANTICANCER EFFECTS OF CITRUS BERGAMIA JUICE IN SH-SY5Y CULTURES
Delle Monache S., Sanità P., Cirmi S., Lombardo G., Ferlazzo N., Angelucci A., Calapai G., Navarra M. |
IN VITRO ANTI-LEUKEMIC ACTIVITY OF HEMIDESMUS INDICUS AND RELATED MOLECULAR MECHANISMS
Turrini E., Ferruzzi L., Poli F., Hrelia P., Fimognari C., Cantelli Forti G. |
IN VITRO STUDY OF SONODYNAMIC AND PHOTODYNAMIC TREATMENT ON HUMAN CANCER CELL LINES
Foglietta F., Canaparo R., Francovich A., Civera P., Ferretti C., Zara G., Serpe L. |
EFFECTS OF OLEUROPEIN AND PERACETYLATED OLEUROPEIN ON THYROID CANCER CELLS
Maggisano V., Bulotta S., Corradino R., Celano M., Maiuolo J., D'Agostino M., Oliverio M., Procopio A., Russo D. |
CLINICAL, PHARMACODYNAMIC AND PHARMACOGENETIC EVALUATION OF DOCETAXEL PLUS PREDNISONE IN COMBINATION WITH METRONOMIC CYCLOPHOSPHAMIDE AND CELECOXIB AS FIRST LINE TREATMENT IN CASTRATION RESISTANT PROSTATE CANCER
Orlandi P., Derosa L., Fioravanti A., Galli L., Di Desidero T., Fontana A., Antonuzzo A., Biasco E., Farnesi A., Falcone A., Danesi R., Bocci G. |
ANTIPROLIFERATIVE AND PRO-APOPTOTIC ACTIVITY OF SUNITINIB ON ENDOTHELIAL AND ON ANAPLASTIC THYROID CANCER CELLS, VIA INHIBITION OF AKT AND ERK1/2 PHOSPHORYLATION AND BY DOWN-REGULATION OF CYCLIN-D1
Di Desidero T., Fioravanti A., Orlandi P., Canu B., Giannini R., Borrelli N., Fontanini G., Basolo F., Francia G., Danesi R., Bocci G. |
COMBINED TREATMENT WITH EVEROLIMUS AND 5-AZA-2′-DEOXYCYTIDINE: A NEW THERAPEUTIC STRATEGY IN MEDULLARY THYROID CANCER.
Dicitore A., Gaudenzi G., Caraglia M., Misso G., Borghi M., Hofland L., Persani L., Vitale G. |
PHENOTYPIZATION OF CYTOCHROME CYP2D6 ACTIVITY WITH DEXTROMETHORPHAN CAN PREDICT TAMOXIFEN ACTIVATION IN BREAST CANCER PATIENTS
Pezzolo E., Bertolaso L., Minicuci N., De Rosa G., Groppa F., Pasini F., Padrini R., Gusella M. |
PHOTOTOXIC ANTITUMOUR PROPERTIES OF RHENIUM PORPHYRIN CONJUGATES
Bergamo A., Spagnul C., Gianferrara T., Alessio E., Alberto R. |
NOVEL SRC KINASE INHIBITORS INHIBIT THE GROWTH OF CD133+ COLORECTAL CANCER CELLS AND MODULATE MICRORNAS EXPRESSION
Pozzesi N., Liberati A., Botta M., Delfino D. |
OUABAIN INDUCES AUTOPHAGIC CELL DEATH IN A549 LUNG CANCER CELLS THROUGH A MECHANISM DEPENDENT ON JNK ACTIVATION
Trenti A., Grumati P., Cusinato F., Orso G., Trevisi L. |
PERORAL DRUG DELIVERY IN CANCER
Ravi Kumar M. |
DISSECTING THE CELLULAR MECHANISMS OF CARDIOTOXICITY BY ANTHRACYCLINE AND TYROSINE KINASE INHIBITORS
Frati C., Falco A., Gervasi A., Graiani G., Lorusso B., Madeddu D., Savi M., Cavalli S., de Angelis A., Piegari E., Urbanek K., Rossi F., Galaverna F., Prezioso L., Lagrasta C., Quaini F. |
IMMUNOLOGICAL MONITORING OF METASTATIC COLORECTAL CANCER PATIENTS UNDERGOING ACTIVE SPECIFIC IMMUNOTHERAPY WITH A POLY-EPITOPE PEPTIDE VACCINE (TSPP) TO THYMIDYLATE SYNTHASE IN COMBINATION WITH GOLFIG CHEMOIMMUNOTHERAPY REGIMEN
Mazza D., Martino C., Micheli L., Giorgi G., Correale P. |
A NEW TN-ANTIGEN MIMETIC CONJUGATED TO SPIONS IS IMMUNOACTIVE
Fallarini S., Richichi B., Manuelli M., Pagliai F., Sangregorio C., Nativi C., Lombardi G. |
RISK OF ADVERSE NEONATAL OUTCOMES AFTER PANDEMIC VACCINATION IN ITALY
Trotta F., Da Cas R., Spila-Alegiani S., Gramegna M., Venegoni M., Zocchetti C., Traversa G. |
SIRT1-REGULATED REST GENE EXPRESSION IN MEDULLOBLASTOMA CELLS
Baiula M., Lombardi S., Spampinato S. |
DIRECT AND INDIRECT PHARMACOLOGICAL REGULATION OF MTOR AFFECTS FATE OF LAM/TSC CELLS. EPITHELIAL TO MESENCHYMAL TRANSITION FEATURES OF LAM/TSC CELLS
Ancona S., Lesma E., Sirchia S., Orpianesi E., Chiaramonte E., Di Giulio A., Gorio A. |
IDENTIFICATION OF SMALL SYNTHETIC ANTI-PYROPTOTIC COMPOUNDS
Miglio G., Bertinaria M., Rogazzo M., Cocco M., Garella D., Di Stilo A., Fantozzi R. |
EPS8: A COMMON TARGET FOR ENDOTHELIAL AND TUMORAL CELLS
Cattaneo M., Cappellini E., Pisoni S., Vicentini L. |
PLATELET RELEASE OF PDGF CAUSES CYCLOOXYGENASE-2 UP-REGULATION IN HT29 COLON CANCER CELLS: INHIBITION BY IMATINIB MESYLATE
Dovizio M., Alberti S., Maier T., Suess B., Steinhilber D., Patrignani P. |
HUMAN LAM/TSC CELLS EFFICIENTLY CAUSE LUNG NODULE FORMATION AND ALVEOLAR DESTRUCTION. PHARMACOLOGICAL COUNTERACTION BY MODULATION OF MTOR ACTIVITY.
Chiaramonte E., Lesma E., Ancona S., Orpianesi E., Di Giulio A., Gorio A. |
